Skip to main content

Table 4 Logistic regression analysis for associations between multimorbidity groups and achievement of T2D treatment targets

From: Multimorbidity and achievement of treatment goals among patients with type 2 diabetes: a primary care, real-world study

 

HbA1c OR (95 % CI)

LDL OR (95 % CI)

sBP OR (95 % CI)

HbA1c OR (95 % CI)

LDL OR (95 % CI)

sBP OR (95 % CI)

HbA1c OR (95 % CI)

LDL OR (95 % CI)

sBP OR (95 % CI)

 

Unadjusted

Model 1a

Model 2b

Multimorbidity

1.34 (1.04–1.71)

2.00 (1.57–2.56)

0.84 (0.61–1.16)

1.47 (1.14–1.89)

1.34 (1.03–1.74)

0.82 (0.59–1.14)

1.32 (1.01–1.70)

1.29 (0.99–1.68)

0.85 (0.61–1.18)

Concordant

1.45 (1.09–1.90)

1.91 (1.46–2.51)

0.86 (0.60–1.22)

1.59 (1.20–2.11)

1.33 (1.00–1.78)

0.82 (0.57–1.18)

1.47 (1.10–1.95)

1.30 (0.98–1.74)

0.84 (0.58–1.20)

Discordant

1.12 (0.81–1.54)

1.25 (0.91–1.72)

0.98 (0.66–1.46)

1.13 (0.81–1.56)

1.22 (0.87–1.70)

0.98 (0.65–1.47)

1.03 (0.74–1.43)

1.19 (0.85–1.66)

0.98 (0.66–1.47)

Concordant and discordant

1.34 (1.04–1.71)

2.15 (1.68–2.76)

0.82 (0.59–1.14)

1.50 (1.15–1.94)

1.36 (1.05–1.78)

0.80 (0.57–1.11)

1.32 (1.01–1.72)

1.31 (1.00–1.72)

0.83 (0.59–1.16)

T2D only

1.0

1.0

1.0

1.0

1.0

1.0

1.0

1.0

1.0

  1. Concordant includes T2D-related diseases, Discordant includes non-T2D-related diseases, and Concordant and discordant includes both
  2. Multimorbidity = one or more diseases in addition to T2D
  3. Significant ORs are bolded
  4. T2D  type 2 diabetes, OR  odds ratio, CI  confidence interval, HbA1c  glycosylated haemoglobin A1c, LDL  low-density-lipoprotein cholesterol, sBP systolic blood pressure
  5. aAdjusted for: age, sex, prescribed medications
  6. bAdjusted for: age, sex, prescribed medications, BMI